Target Name: MIR183
NCBI ID: G406959
Review Report on MIR183 Target / Biomarker Content of Review Report on MIR183 Target / Biomarker
MIR183
Other Name(s): miRNA183 | MIRN183 | microRNA 183 | miR-183 | hsa-miR-183-5p | MicroRNA 183 | hsa-miR-183-3p | hsa-mir-183

MIR183: A promising drug target and biomarker for cancer

Mir183, also known as miRNA183, is a microRNA (miRNA) that has been shown to play a critical role in the development and progression of various diseases, including cancer. Its unique structure and biology have made it an attractive target for drug development. In In this article, we will explore the biology and potential of MIR183 as a drug target and biomarker for cancer.

MIR183: The microRNA with a big impact

MIR183 is a non-coding RNA molecule that contains 20 amino acid residues. It is expressed in various tissues and cells of the body and is involved in the regulation of gene expression. The most significant function of MIR183 is its ability to target specific mRNAs for degradation. This process is called exonuclease activity, which allows MIR183 to selectively break down target mRNAs.

MIR183 has been shown to play a critical role in the development and progression of various diseases, including cancer. For example, MIR183 has been shown to promote the growth and survival of cancer cells. It has also been shown to contribute to the development of cancer -associated fibrosis (CAF), a condition that affects the connective tissue of the body and is associated with various diseases, including cancer.

MIR183 as a drug target: Potential and challenges

MIR183 has the potential to be a drug target for cancer due to its role in the development and progression of cancer. One of the challenges in developing MIR183 as a drug target is its expression in various tissues and cells of the body, which makes it difficult to study its effects. Another challenge is the lack of understanding of its cellular and molecular mechanisms of action, which makes it difficult to predict its effects in different contexts.

Despite these challenges, researchers are actively working to develop MIR183 as a drug target for cancer. One approach is to use small molecules to target MIR183, which can modulate its expression and activity. Researchers are also using techniques such as RNA interference and CRISPR/Cas9 genome editing to study the role of MIR183 in different contexts.

MIR183 as a biomarker: Potential and applications

MIR183 has also been shown to be a potential biomarker for cancer. Its expression has been shown to be associated with the development and progression of various cancers, including breast, ovarian, and colorectal cancers. This makes MIR183 a promising target for cancer biomarkers.

One of the potential applications of MIR183 is its use as a diagnostic marker for cancer. Researchers are exploring the use of MIR183 as a diagnostic probe to detect cancer at an early stage. Another potential application of MIR183 is its use as a target for cancer immunotherapy.

In conclusion, MIR183 is a microRNA that has the potential to be a drug target for cancer due to its role in the development and progression of cancer. Despite the challenges in developing MIR183 as a drug target, researchers are actively working to use it as a biomarker for cancer. Further studies are needed to fully understand its mechanisms of action and its potential as a drug or biomarker for cancer.

Protein Name: MicroRNA 183

The "MIR183 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR183 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1